Advanced

Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma.

Lindgren, David LU ; Sjödahl, Gottfrid LU ; Lauss, Martin LU ; Staaf, Johan LU ; Chebil, Gunilla; Lövgren, Kristina LU ; Gudjonsson, Sigurdur LU ; Liedberg, Fredrik LU ; Hultman Patschan, Oliver LU and Månsson, Wiking LU , et al. (2012) In PLoS ONE 7(6).
Abstract
Similar to other malignancies, urothelial carcinoma (UC) is characterized by specific recurrent chromosomal aberrations and gene mutations. However, the interconnection between specific genomic alterations, and how patterns of chromosomal alterations adhere to different molecular subgroups of UC, is less clear. We applied tiling resolution array CGH to 146 cases of UC and identified a number of regions harboring recurrent focal genomic amplifications and deletions. Several potential oncogenes were included in the amplified regions, including known oncogenes like E2F3, CCND1, and CCNE1, as well as new candidate genes, such as SETDB1 (1q21), and BCL2L1 (20q11). We next combined genome profiling with global gene expression, gene mutation, and... (More)
Similar to other malignancies, urothelial carcinoma (UC) is characterized by specific recurrent chromosomal aberrations and gene mutations. However, the interconnection between specific genomic alterations, and how patterns of chromosomal alterations adhere to different molecular subgroups of UC, is less clear. We applied tiling resolution array CGH to 146 cases of UC and identified a number of regions harboring recurrent focal genomic amplifications and deletions. Several potential oncogenes were included in the amplified regions, including known oncogenes like E2F3, CCND1, and CCNE1, as well as new candidate genes, such as SETDB1 (1q21), and BCL2L1 (20q11). We next combined genome profiling with global gene expression, gene mutation, and protein expression data and identified two major genomic circuits operating in urothelial carcinoma. The first circuit was characterized by FGFR3 alterations, overexpression of CCND1, and 9q and CDKN2A deletions. The second circuit was defined by E3F3 amplifications and RB1 deletions, as well as gains of 5p, deletions at PTEN and 2q36, 16q, 20q, and elevated CDKN2A levels. TP53/MDM2 alterations were common for advanced tumors within the two circuits. Our data also suggest a possible RAS/RAF circuit. The tumors with worst prognosis showed a gene expression profile that indicated a keratinized phenotype. Taken together, our integrative approach revealed at least two separate networks of genomic alterations linked to the molecular diversity seen in UC, and that these circuits may reflect distinct pathways of tumor development. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
PLoS ONE
volume
7
issue
6
publisher
Public Library of Science
external identifiers
  • wos:000305351700077
  • pmid:22685613
  • scopus:84862027456
ISSN
1932-6203
DOI
10.1371/journal.pone.0038863
language
English
LU publication?
yes
id
a986fe29-fc05-42f4-87a1-a779c3cd8ab5 (old id 2859603)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/22685613?dopt=Abstract
date added to LUP
2012-07-04 13:18:27
date last changed
2017-11-19 03:56:33
@article{a986fe29-fc05-42f4-87a1-a779c3cd8ab5,
  abstract     = {Similar to other malignancies, urothelial carcinoma (UC) is characterized by specific recurrent chromosomal aberrations and gene mutations. However, the interconnection between specific genomic alterations, and how patterns of chromosomal alterations adhere to different molecular subgroups of UC, is less clear. We applied tiling resolution array CGH to 146 cases of UC and identified a number of regions harboring recurrent focal genomic amplifications and deletions. Several potential oncogenes were included in the amplified regions, including known oncogenes like E2F3, CCND1, and CCNE1, as well as new candidate genes, such as SETDB1 (1q21), and BCL2L1 (20q11). We next combined genome profiling with global gene expression, gene mutation, and protein expression data and identified two major genomic circuits operating in urothelial carcinoma. The first circuit was characterized by FGFR3 alterations, overexpression of CCND1, and 9q and CDKN2A deletions. The second circuit was defined by E3F3 amplifications and RB1 deletions, as well as gains of 5p, deletions at PTEN and 2q36, 16q, 20q, and elevated CDKN2A levels. TP53/MDM2 alterations were common for advanced tumors within the two circuits. Our data also suggest a possible RAS/RAF circuit. The tumors with worst prognosis showed a gene expression profile that indicated a keratinized phenotype. Taken together, our integrative approach revealed at least two separate networks of genomic alterations linked to the molecular diversity seen in UC, and that these circuits may reflect distinct pathways of tumor development.},
  articleno    = {e38863},
  author       = {Lindgren, David and Sjödahl, Gottfrid and Lauss, Martin and Staaf, Johan and Chebil, Gunilla and Lövgren, Kristina and Gudjonsson, Sigurdur and Liedberg, Fredrik and Hultman Patschan, Oliver and Månsson, Wiking and Fernö, Mårten and Höglund, Mattias},
  issn         = {1932-6203},
  language     = {eng},
  number       = {6},
  publisher    = {Public Library of Science},
  series       = {PLoS ONE},
  title        = {Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma.},
  url          = {http://dx.doi.org/10.1371/journal.pone.0038863},
  volume       = {7},
  year         = {2012},
}